140 filings
Page 3 of 7
8-K
7cguwtbxop 27fz
21 Jun 22
Regulation FD Disclosure
10:30am
8-K
2qblivqzvc9
13 Apr 22
Regulation FD Disclosure
8:00am
8-K
ye0 abcvgbw3qxvu
23 Feb 22
Regulation FD Disclosure
12:02pm
8-K
7bmh2hdj53bd5hy
8 Feb 22
MyMD Pharmaceuticals Announces Positive Clinical Data in Advance of Upcoming Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan
9:20am
8-K
uejv5jasmypg
5 Jan 22
MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia
9:28am
8-K
25yd8q
29 Dec 21
Submission of Matters to a Vote of Security Holders
5:28pm
8-K
f49smxk8f1lpafv
3 Dec 21
Regulation FD Disclosure
4:30pm
8-K
4hb 0bzpik8w4vl59
16 Nov 21
MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan
9:25am
8-K
6r38t vsx
12 Nov 21
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
5:00pm
8-K
iqkdg7pqfm
26 Oct 21
Regulation FD Disclosure
11:00am
8-K
dc2 hq9ol
19 Oct 21
Regulation FD Disclosure
10:30am
8-K
fevqx523
5 Oct 21
MyMD Pharmaceuticals to Detail its Two Upcoming Phase 2 Trials
10:00am
8-K
tlvoe9 pt87f9
22 Sep 21
MyMD Pharmaceuticals Announces New Data Demonstrating 8,000
12:52pm
8-K
qei275bak03hkf8
13 Sep 21
MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan
5:30pm
8-K
f8ynk
3 Sep 21
Departure of Directors or Certain Officers
4:38pm
8-K
rzf94eihj4yi4aoiu4dt
2 Jul 21
Departure of Directors or Certain Officers
5:00pm
8-K/A
9cmlqzrvla1ev0n8tvd
2 Jul 21
Financial Statements and Exhibits
4:00pm
8-K
0l8b82j0 6spzudj
13 May 21
Regulation FD Disclosure
6:20am
8-K
yhfxss
21 Apr 21
Akers Biosciences and MyMD Pharmaceuticals Announce Stockholder Approval of Merger
9:56pm
8-K
ewpn3alk
16 Apr 21
Submission of Matters to a Vote of Security Holders
4:00pm